FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1963809166> ?p ?o ?g. }

• W1963809166 endingPage "42" @default.
• W1963809166 startingPage "35" @default.
• W1963809166 abstract "Reviews in Medical VirologyVolume 2, Issue 1 p. 35-42 Forum Neutralization of human immunodeficiency virus Jane A. Mckeating, Jane A. Mckeating Institute of Cancer Research, Chester Beatty Laboratories, 237 Fulham Road, London SW3 6JB, UKSearch for more papers by this author Jane A. Mckeating, Jane A. Mckeating Institute of Cancer Research, Chester Beatty Laboratories, 237 Fulham Road, London SW3 6JB, UKSearch for more papers by this author First published: March 1992 https://doi.org/10.1002/rmv.1980020106Citations: 5AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Dalgleish, A., Beverley, P. C. L., Clapham, P. R., Crawford, D. H., Greaves, M. F. and Weiss, R. A. (1984). The CD4 antigen is an essential component of the receptor for the AIDS retrovirus. Nature, 312, 763–767. 2 Klatzman, D., Champagne, E., Chamaret, S. et al. (1984). T lymphocyte T4 molecule behaves as the receptor for the AIDS virus. Nature, 312, 767–768. 3 Clapham, P. R. (1991). Human immunodeficiency virus infection of non-haematopoietic cells and CD4-independent entry. Rev. Med. Virol., 1. 4 Geyer, H., Holschbach, C., Hunsman, G. and Schneiden, J. (1988). Carbohydrates of human immunodeficiency virus. J. Biol. Chem., 263, 11760–11767. 5 Lasky, L. A., Nakamura, G. M., Smith, D. H. et al. (1987). Delineation of a region of the human immunodeficiency virus type I gp120 glycoprotein critical for interaction with the CD4 receptor. Cell, 50, 975–985. 6 Camerini, D. and Seed, B. (1990). A CD4 domain important for HIV-mediated syncytium formation lies outside the virus binding site. Cell, 60, 747–754. 7 Healey, D., Dianda, L., Moore, J. P. et al. (1990). Novel anti-CD4 monoclonal antibodies separate HIV infection and fusion of CD4+ cells from virus binding. J. Exp. Med., 172, 1273–1279. 8 Ashorn, J., Deen, C. K., Chaikin, M. A. et al. (1989) Identification of the residues in CD4 critical for the binding of HIV. Cell, 57, 469–481. 9 Clapham, P. R., Blanc, D. and Weiss, R. A. (1991). Specific cell surface requirements for infection of CD4 positive cells by HIV-1, HIV-2 and SIV. Virology, 181, 703–715. 10 Gallaher, W. R. (1987). Detection of fusion peptide sequence in the transmembrane protein of human immunodeficiency virus. Cell, 50, 327–328. 11 Stein, B. S., Gowda, S., Lifson, J., Penhallow, R., Bensch, K. and Engelman, E. (1987). pH-independent HIV entry into CD4 positive cells via virus envelope fusion to the plasma membrane. Cell, 49, 659–668. 12 McClure, M. Q., Marsh, M. and Weiss, R. A. (1988). Human immunodeficiency virus infection of CD4-bearing cells occurs by a pH-independent mechanism. EMBO J., 7, 513–518. 13 Weiss, R. A., Clapham, P. R., Weber, J. N., Dalgleish, A. G., Lasky, L. and Berman, P. W. (1986). Variable and conserved neutralisation antigens of human immunodeficiency virus. Nature, 324, 572–575. 14 Matthews, T. J., Langlois, A. J., Robey, W. G. et al. (1986). Restricted neutralisation of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein. Proc. Natl Acad. Sci. USA, 83, 9709–9713. 15 Wong-Staal, F., Shaw, G. M., Hahn, B. H. et al. (1985). Genomic diversity of human T-lymphotrophic virus type III (HTLV-III). Science, 229, 759–762. 16 Alizon, M., Wain-Hobson, S., Montagnier, L. and Sonigo, P. (1986). Genetic variability of the AIDS virus: nucleotide sequence analysis of two isolates from African patients. Cell, 46, 63–74. 17 Starcich, D. H., Hahn, B. H., Shaw, G. M. et al. (1986). Identification and characterisation of conserved and variable regions in the envelope gene of HTLV-III/ LAV, the retrovirus of AIDS. Cell, 45, 637–648. 18 Willey, R. L., Rutledge, R. A., Dias, S. et al. (1986). Identification of conserved and divergent domains within the envelope gene of the acquired immunodeficiency syndrome retrovirus. Proc. Natl Acad. Sci. USA, 83, 5038–5042. 19 Hahn, B. H., Shaw, G. M., Taylor, M. E. et al. (1986). Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDS. Science, 232, 1548–1553. 20 Saag, M. S., Hahn, B. H., Gibbons, J. et al. (1988). Extensive variation of human immunodeficiency virus type-I in vivo. Nature, 334, 440–444. 21 Goodenow, M., Huet, T., Saurin, W., Kwok, S., Sninsky, J. and Wain-Hobson, S. (1989). HIV-1 isolates are rapidly evolving quasispecies: evidence for viral mixtures and preferred nucleotide substitutions. J. AIDS, 2, 344–352. 22 Meyerhans, A., Cheynier, R., Albert, J. et al. (1989). Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential isolation. Cell, 58, 901–910. 23 Preston, B., Poisez, B. and Loeb, L. (1988). Fidelity of HIV-1 RT. Science, 242, 1165–1167. 24 Roberts, J., Bebenek, K. and Kunkel, T. (1988). The accuracy of RT from HIV-1. Science, 242, 1171–1173. 25 Myers, G. (1990). Human Retrovirus and AIDS. Los Alomos National Laboratory, Los Alomos, NM. 26 Modrow, S., Hahn, H. B., Shaw, G., Gallo, R. C., Wong-Staal, F. and Wolf, H. (1987). Computer assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions. J. Virol., 61, 570–578. 27 Weiss, R. A., Clapham, P. R., Cheingsong-Popov, R. et al. (1985). Neutralisation of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature, 316, 69–72. 28 Robert-Guroff, M., Brown, M. and Gallo, R. C. (1985). HTLV-III neutralising antibodies in patients with AIDS and AIDS related complex. Nature, 316, 72–74. 29 Spear, G. T., Sullivan, B., Landay, A. I. and Lint, T. F. (1990). Neutralization of human immunodeficiency virus type I by complement occurs by viral lysis. J. Virol., 64, 5869–5873. 30 Nara, P. L., Robey, W. G., Pyle, S. et al. (1988). Purified envelope glycoproteins from human immunodeficiency virus type I variants induce individual type specific neutralizing antibodies. J. Virol., 62, 2622–2628. 31 Klinman, D. M., Higgins, K. W. and Conover, J. (1991). Sequential immunizations with rgp120′s from independent isolates of human immunodeficiency virus type I induce the preferential expansion of broadly cross reactive B cells. J. Exp. Med., 173, 881–887. 32 Haigwood, N. L., Shuster, J. R., Moore, G. K. et al. (1990). Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralising antibodies. AIDS Res. Hum. Retroviruses, 6, 855. 33 Albert, J., Abrahasson, B., Nagy, K., Aurelius, E., Gaines, H., Nystrom, G. and Fenyo, E. M. (1990). Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS, 4, 107–112. 34 Tremblay, M. and Wainberg, M. A. (1990). Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera. J. Infect. Dis., 162, 735–737. 35 Nara, P. L., Robey, W. G., Arthur, L. O. et al. (1987). Persistent infection of chimpanzees with HIV: serolo-gical responses and properties of re-isolated viruses. J. Virol., 61, 3173–3180. 36 Albert, J., Gaines, H., Sonnerborg, G. H. et al. (1987). Isolation of human immunodeficiency virus (HIV) from plasma during HIV infection. J. Med. Virol. 23, 67–73. 37 Gaines, H., Albert, J., Von Sydow, M. et al. (1987). HIV antigenemia and virus isolation from plasma during primary HIV-1 infection. Lancet, i, 1317. 38 Cheng-Mayer, C., Seto, D., Tateno, M. and Levy, J. A. (1989). Biologic features of HIV-1 that correlate with virulence in the host. Science, 240, 80–82. 39 Tersmette, M., Gruters, R. A., de Wolf, F. et al. (1989). Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome obtained from studies on a panel of sequential isolates. J. Virol., 63, 2118–2125. 40 Fenyo, E. M., Morfeldt-Manso, L., Chiodi, F. et al. (1988). Distinct replicative and cytopathic characteristics of human immunodeficiency isolates. J. Virol., 62, 4414–4419. 41 Emini, E. A., Nara, P. L., Schleif, W. A. et al. (1990). Antibody-mediated in vitro neutralization of human immunodeficiency virus type I abolishes infectivity for chimpanzees. J. Virol., 64, 3674–3678. 42 Berman, P., Gregory, T., Riddle, L. et al. (1990). Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant gp120 but not gp160. Nature, 345, 622–628. 43 McKeating, J. A., McKnight, A. and Moore, J. P. (1991a). Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type I: effects on infectivity and neutralization. J. Virol. 65, 852–860. 44 Layne, S. P., Merges, M. J., Dembo, M., Spouge, J. L. and Nara, P. L. (1991). HIV requires multiple gp120 molecules for CD4-mediated infection. Nature, 346, 277–279. 45 Layne, S. P., Merge, M. J., Spouge, J. L., Dembo, M. and Nara, P. L. (1991). Blocking of human immunodeficiency virus infection depends on cell density and viral stock age. J. Virol., 65, 3293–3300. 46 Geysen, H. M., Meloen, R. H., Barteling, S. J. et al. (1984). Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid. Proc. Natl Acad. Sci. USA, 81, 3998–4002. 47 Van Tijn, D., Boucher, C., Bakker, M. and Goudsmit, J. (1989). Antigenicity of linear B-cell epitopes in the C1, V1 and V3 region of gp120. J. AIDS, 2, 303–306. 48 Xu, J. Y., Corny, M. K., Palker, T., Karwowska, S. and Zolla-Pazner, S. (1991). Epitope mapping of the immunodominant domains of gp41, the transmem-brane protein of HIV-1, using ten human monoclonal antibodies. J. Virol., 65, 4832–4838. 49 Robinson, W. E., Montefiori, D. C., Mitchell, W. M. et al. (1988). Antibody-dependent enhancement of human immunodeficiency virus type I infection. Lancet, i, 790–794. 50 Takeda, A., Tuazon, C. U., Ennis, F. A. et al. (1988). Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science, 242, 580–583. 51 Homsy, J., Tateno, M. and Levy, J. A. (1988). Antibody-dependent enhancement of HIV infection. Lancet, i, 1285–1286. 52 Homsy, J., Meyer, M. and Levy, J. A. (1990). Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals. J. Virol., 64, 1437–1440. 53 Nara, P. L., Layne, S. P., Garrity, R. R. and Goudsmit, J., (1991). Neutralization of HIV-1: a paradox of humoral proportions. FASEB J., in press. 54 McKeating, J. A., Moore, J. P., Willey, R. A., Putney, S., Martin, M. A. and Weiss, R. A. (1989a). Predicted interaction of V3 neutralization loop with other regions of the HIV-1 envelope. In, Retroviruses of Human AIDS and Related Animal Diseases, ed. by M. Girard and L. Valette, pp. 195–202. Pasteur Vaccines, Paris. 55 Rusche, J. R., Javaherian, K., McDanal, C. et al. (1988). Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope. 56 Palker, T. J., Clark, M. E., Langlois, A. J. et al. (1988). Type-specific neutralization of the human immunodeficiency virus with antibodies to env-coded synthetic peptides. Proc. Natl Acad. Sci. USA, 85, 2107–2114. 57 Goudsmit, J., Thiriart, C., Smit, L., Bruck, C. and Gibbs, C. J. (1988). Temporal development of cross-neutralization between HTLV-IIIB and HTLV-IIIRF in experimentally infected chimpanzees. Vaccines, 6, 229–232. 58 Zagury, D., Bernard, J., Cheynier, R. et al. (1988). A group-specific anamnestic immune response reaction against HIV induced by a candidate vaccine against AIDS. Nature, 332, 728–731. 59 Goudsmit, J., Debouck, C., Meloen, R. H. et al. (1988). Human immunodeficiency virus type I neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc. Natl Acad. Sci. USA, 85, 4478–4482. 60 Steimer, K. S., van Nest, G. A., Haigwood, N. L. et al. (1988). Recombinant env and gag polypeptides in characterising HIV-1 neutralising antibodies. in, Vaccines 1988, ed. by H. Ginsberg, F. Brown et al., pp. 347–355. Cold Spring Harbour, NY. 61 Haigwood, N. L., Barker, G. B., Higgins, K. W. et al. (1990). Evidence for neutralising antibodies directed against conformational epitopes of HIV-1 gp120. in, Vaccines 1990: Modern Approaches to New Vaccines Including Prevention of AIDS, ed. by F. Brown, pp. 313–320. Cold Spring Harbour, New York. 62 Meloen, R. H., Liskamp, R. M. and Goudsmit, J. (1989). Specificity and function of the individual amino acids of an important determinant of human immunodeficiency virus type I that induces neutralizing activity. J. Gen. Virol., 70, 1505–1512. 63 LaRosa, G. J., Davide, J. P., Weinhold, K. et al. (1990). Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science, 249, 932–935. 64 Scott, C., Silver, S., Profy, A. et al. (1990). A human monoclonal antibody which recognizes the V3 region of gp120 and neutralizes the HTLV-III MN strain. Proc. Natl Acad. Sci. USA, 87, 8597–8601. 65 Gorny, M. K., Xu, J. Y., Gianakakos, V. et al. (1991). Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type I envelope glycoprotein. Proc. Natl Acad. Sci. USA, 88, 3238–3242. 66 Rossi, P., Moschese, V., Broliden, P. A. et al. (1989). Presence of maternal antibodies to human immunodeficiency virus I envelope glycoprotein gp120 epitopes correlates with the uninfected status of children born to seropositive mothers. Proc. Natl Acad. Sci. USA, 86, 8055–8058. 67 Nara, P. L., Smit, L., Dunlop, N. et al. (1990). Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees. J. Virol., 64, 3779–3791. 68 McKeating, J. A., Gow, J., Goudsmit, J., Pearl, L., Mulder, C. and Weiss, R. A. (1989). Characterisation of HIV-1 neutralization escape mutants. AIDS, 3, 777–784. 69 Willey, R. L., Ross, E. K., Buckler-White, A. J., Theodore, T. S. and Martin, M. A. (1989). Functional interaction of constant and variable domains of HIV-1 gp120. J. Virol., 63, 3595–3600. 70 Hwang, S. S., Boyle, T. J., Lyerly, H. K. and Cullen, B. R. (1991). Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science, 253, 71–73. 71 Clements, G., Price-Jones, M., Stephens, P., Sutton, C. et al. (1991). The V3 loops of the HIV-1 and HIV-2 surface glycoproteins contain proteolytic cleavage sites: a possible function in viral fusion. AIDS Res. Human Retroviruses, 7, 3–16. 72 Koito, A., Hattori, T., Murakami, T. et al. (1989). A neutralising epitope of human immunodeficiency virus type 1 has homologous amino acid sequences with the active site of inter-a-trypsin inhibitor. Int. Immunol., 1, 613–618. 73 Hattori, T., Koito, A., Takatsuki, K., Kido, H. and Katanuma, N. (1989). Involvement of tryptase-related cellular protease(s) in human immunodeficiency virus type I infection. FEBS Lett., 248, 48–52. 74 Kido, H., Fukutomi, A. and Katunuma, N. (1990). A novel membrane-bound serine esterase in human T4+ lymphocytes immunologically reactive with antibody inhibiting syncytia induced by HIV-1. J. Biol. Chem., 265, 21979–21985. 75 Putney, S. D. and McKeating, J. A. (1990). Antigenic variation in HIV. AIDS, 4 (Suppl. 1), 129–136. 76 Moore, J. P., McKeating, J. A., Norton, W. A. and Sattentau, Q. (1991). Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4. J. Virol., 65, 1133–1140. 77 Thomas, D. J., Wall, J. S., Hainfeld, J. F. et al. (1991). Gp160, the envelope glycoprotein of human immunodeficiency virus type I, is a dimer of 125 Kilodalton subunits stabilized through interactions between their gp41 domains. J. Virol., 65, 3797–3803. 78 Gelderblom, H. R., Ozel, M. and Pauli, G. (1989). Morphogenesis and morphology of HIV, structure-function relations. Arch. Virol., 106, 1–13. 79 Weiss, C. D., Levy, J. A. and White, J. M. (1990). Oligomeric organization of gp120 on infectious human immunodeficiency type I particles. J. Virol., 64, 5674–5677. 80 Rey, M. A., Krust, B., Laurent, A. G., Montagnier, L. and Hovanessian, A. G. (1989). Characterization of human immunodeficiency virus type 2 envelope glycoproteins: dimerization of the glycoprotein precursor during processing. J. Virol., 63, 647–658. 81 Pinter, A., Honnen, W. J., Tilley, S. A., Bona, C., Zaghounani, H., Gorny, M. K. and Zolla-Pazner, S. (1989). Oligomeric structure of gp41, the transmem-brane protein of human immunodeficiency virus type I. J. Virol., 63, 2674–2679. 82 Schawaller, M., Smith, C. E., Skehel, J. J. and Wiley, D. C. (1989). Studies with cross-linking reagents on the oligomeric structure of the env-glycoprotein of HIV. Virology, 172, 367–369. 83 McDougal, J. S., Nicholson, J. K. A., Cross, G. D., Kennedy, M. S. and Mawle, A. C. (1986). Binding of the human retrovirus HTLV-III/ARV/HIV to the CD4 molecule; conformational dependence, epitope mapping, antibody inhibition and potential for idiotypic mimicry. J. Immunol., 137, 2937–2944. 84 Skinner, M. A., Langlois, A. J., McDanal, C., McDougal, J. S., Bolognesi, D. P. and Matthews, T. J. (1988). Neutralising antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4. J. Virol., 62, 4195–4200. 85 Schnittman, S. M., Lane, H. C., Roth, J. et al. (1988). Characterisation of gp120 binding to CD4 and an assay that measures ability of sera to inhibit this binding. J. Immunol., 141, 4181–4186. 86 Back, N. K. T., Thiriart, C., Delers, A., Ramantarsing, C., Bruck, C. and Goudsmit, J. (1990). Association of antibodies blocking HIV-1 gp160-sCD4 attachment with virus neutralizing activity in human sera. J. Med. Virol., 31, 200–208. 87 Kowalski, M., Potz, J., Basairipour, L. et al. (1987). Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. Science, 237, 1351–1355. 88 Cordonnier, A., Riviere, T., Montagnier, L. and Emerman, M. (1989). Effects of mutations in hyper-conserved regions of the extracellular glycoprotein of human immunodeficiency virus type 1 glycoprotein precursor. J. Virol., 63, 4464–4468. 89 Sun, N. C., Ho, D. D., Sun, C. R. Y. et al. (1989). Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of HIV-1 gp120. J. Virol., 63, 3579–3585. 90 Ardman, B., Kowalski, M., Bristol, J., Haseltine, W. and Sodroski, J. (1990). Effects on CD4 binding of antipeptide antisera to the fourth and fifth conserved domains of HIV-1 gp120. J AIDS, 3, 206–214. 91 Cordell, J., Moore, J. P., Dean, C. J., Klasse, P. J., Weiss, R. A. and McKeating, J. A. (1991). Rat monoclonal antibodies to non-overlapping epitopes of human immunodeficiency virus type I gp120 block CD4 binding in vitro. Virology, 185, 72–79. 92 Ho, D. D., McKeating, J. A., Li, X. L. et al. (1991). Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type I neutralisation by a human monoclonal antibody. J. Virol., 65, 489–493. 93 Tilley, S. A., Honnen, W. J., Racho, M. E., Hilgartner, M. and Pinter, A. (1991). A human monoclonal antibody against the CD4 binding site of HIV-1 gp120 exhibits potent, broadly neutralizing activity. Res. Virol., 142, 247–259. 94 Olshevsky, U., Helseth, M., Furman, C., Li, J., Haseltine, W. and Sodroski, J. (1990). Identification of individual human immunodeficiency virus type I gp120 amino acids important for CD4 binding. J. Virol., 64, 5701–5707. 95 Schooley, R. T., Merigan, T. C., Gaut, P. et al. (1990). Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS related complex. A phase I-II escalating dosage trial. Ann. Intern. Med., 112, 247–253. 96 Kahn, J. O., Allan, J. D., Hadges, T. L. et al. (1990). The safety and pharmokinetics of recombinant soluble CD4 (sCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Ann. Intern. Med., 112, 254–261. 97 Daar, E. S., Li, X. L., Moudgil, T. and Ho, D. D. (1990). High concentrations of recombinant soluble CD4 are required to neutralize primary HIV-1 isolates. Proc. NatlAcad. Sci. USA, 87, 6574–6578. 98 Kirsch, R., Hart, T. K., Ellens, H. et al. (1990). Morphometric analysis of recombinant soluble CD4 mediated release of the envelope glycoprotein gp120 from HIV-1. AIDS Res. Hum. Retroviruses, 6, 1209–1212. 99 Hart, T. K., Kirsch, R. and Ellens, H. (1991). CD4-HIV-1 interactions: binding of soluble CD4 to HIV-1 infected cells induces shedding of envelope glycoprotein gp120. Proc. Natl Acad. Sci. USA, 88, 2189–2193. 100 Moore, J. P., McKeating, J. A., Weiss, R. A. and Sattentau, Q. J. (1990). Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science, 250, 1139–1142. 101 Freed, E. O., Myers, D. J. and Risser, R. (1990). Characterisation of the fusion domain of the human immunodeficiency virus type 1 envelope glycoprotein gp41. Proc. Natl Acad. Sci. USA 87, 4650. 102 Reitz, M. A., Wilson, C., Naugle, C., Gallo, R. C. and Robert-Guroff, M. (1988). Generation of a neutralization-resistant variant of HIV-1 is due to a point mutation in the envelope gene. Cell, 54, 57–63. 103 Wilson, C., Reitz, M. A., Aldrich, K. et al. (1990). The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type I does not constitute a neutralization epitope. J. Virol., 64, 3240–3248. 104 Helseth, E., Olshevsky, U., Furman, C. and Sodroski, J. (1991). Human immunodeficiency virus type I gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein. J. Virol., 65, 2119–2123. 105 Chanh, T. C., Dreesman, G. R., Kanda, P. et al. (1986). Induction of anti-HIV neutralising antibodies by synthetic peptides. EMBO J., 5, 3065–3071. 106 Dalgleish, A. G., Chanh, T. C., Kennedy, R. C., Kanda, P., Clapham, P. R. and Weiss, R. A. (1988). Neutralization of diverse HIV-1 strains by monoclonal antibodies raised against a gp41 synthetic peptide. Virology, 165, 209–215. 107 Evans, D. J., McKeating, J., Meredith, J. M. et al. (1989). An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralising antibodies. Nature, 339, 385–388. 108 Haffar, O., Dowbenko, D., Berman, P. et al. (1988). Topogenic analysis of the human immunodeficiency virus type I envelope glycoprotein, gp160, in micro-somal membranes. J. Cell. Biol., 107, 1677–1687. Citing Literature Volume2, Issue1March 1992Pages 35-42 ReferencesRelatedInformation" @default.
• W1963809166 created "2016-06-24" @default.
• W1963809166 creator A5056903505 @default.
• W1963809166 date "1992-03-01" @default.
• W1963809166 modified "2023-09-27" @default.
• W1963809166 title "Neutralization of human immunodeficiency virus" @default.
• W1963809166 cites W108460990 @default.
• W1963809166 cites W1487880751 @default.
• W1963809166 cites W1502480625 @default.
• W1963809166 cites W1504915326 @default.
• W1963809166 cites W1506104034 @default.
• W1963809166 cites W1514857866 @default.
• W1963809166 cites W1516701091 @default.
• W1963809166 cites W1519895420 @default.
• W1963809166 cites W1561165694 @default.
• W1963809166 cites W1601713328 @default.
• W1963809166 cites W1656939007 @default.
• W1963809166 cites W1693544388 @default.
• W1963809166 cites W1739595091 @default.
• W1963809166 cites W176140375 @default.
• W1963809166 cites W1768734130 @default.
• W1963809166 cites W1827178381 @default.
• W1963809166 cites W1895363198 @default.
• W1963809166 cites W1899501273 @default.
• W1963809166 cites W1909984710 @default.
• W1963809166 cites W1912026111 @default.
• W1963809166 cites W1915033188 @default.
• W1963809166 cites W1916975350 @default.
• W1963809166 cites W1933773138 @default.
• W1963809166 cites W1948737260 @default.
• W1963809166 cites W1966554490 @default.
• W1963809166 cites W1968679635 @default.
• W1963809166 cites W1970121767 @default.
• W1963809166 cites W1971333195 @default.
• W1963809166 cites W1973013569 @default.
• W1963809166 cites W1974053173 @default.
• W1963809166 cites W1974138678 @default.
• W1963809166 cites W1976564230 @default.
• W1963809166 cites W1979050229 @default.
• W1963809166 cites W1980259340 @default.
• W1963809166 cites W1981026726 @default.
• W1963809166 cites W1981164507 @default.
• W1963809166 cites W1982794770 @default.
• W1963809166 cites W1986159600 @default.
• W1963809166 cites W1986865717 @default.
• W1963809166 cites W1989658240 @default.
• W1963809166 cites W1991539551 @default.
• W1963809166 cites W1995249527 @default.
• W1963809166 cites W1996225916 @default.
• W1963809166 cites W2007644904 @default.
• W1963809166 cites W2014317403 @default.
• W1963809166 cites W2020231665 @default.
• W1963809166 cites W2020702723 @default.
• W1963809166 cites W2026066319 @default.
• W1963809166 cites W2026990241 @default.
• W1963809166 cites W2029976935 @default.
• W1963809166 cites W2031125892 @default.
• W1963809166 cites W2039028257 @default.
• W1963809166 cites W2041389140 @default.
• W1963809166 cites W2047819393 @default.
• W1963809166 cites W2048574795 @default.
• W1963809166 cites W2049836668 @default.
• W1963809166 cites W2051019142 @default.
• W1963809166 cites W2051792858 @default.
• W1963809166 cites W2053667638 @default.
• W1963809166 cites W2054314380 @default.
• W1963809166 cites W2054724326 @default.
• W1963809166 cites W2056235838 @default.
• W1963809166 cites W2059599036 @default.
• W1963809166 cites W2059778209 @default.
• W1963809166 cites W2062264441 @default.
• W1963809166 cites W2065740427 @default.
• W1963809166 cites W2069407559 @default.
• W1963809166 cites W2069761065 @default.
• W1963809166 cites W2079414250 @default.
• W1963809166 cites W2080557596 @default.
• W1963809166 cites W2080706877 @default.
• W1963809166 cites W2081347192 @default.
• W1963809166 cites W2082678300 @default.
• W1963809166 cites W2086603942 @default.
• W1963809166 cites W2086725873 @default.
• W1963809166 cites W2088403913 @default.
• W1963809166 cites W2089906160 @default.
• W1963809166 cites W2090126383 @default.
• W1963809166 cites W2095078755 @default.
• W1963809166 cites W2097238654 @default.
• W1963809166 cites W2108385781 @default.
• W1963809166 cites W2109210467 @default.
• W1963809166 cites W2110917275 @default.
• W1963809166 cites W2113282092 @default.
• W1963809166 cites W2114049392 @default.
• W1963809166 cites W2114279162 @default.
• W1963809166 cites W2123406253 @default.
• W1963809166 cites W2127776899 @default.
• W1963809166 cites W2132936712 @default.
• W1963809166 cites W2136595144 @default.
• W1963809166 cites W2137779300 @default.
• W1963809166 cites W2149464124 @default.

• next